Biologics (including biosimilars), vaccines, and gene therapy scale-up and manufacturing processes will be the goals of the BioTherapeutics Pharmaceutical Sciences facility, with groundbreaking having occurred at a location in Chesterfield, MO. The 295,000-sq. ft. facility will include state-of-the-art analytical capabilities, says the company; therapeutic targets include oncology, rare diseases, internal medicine, inflammation and immunology.
While far from the biotech centers on the US coasts, Pfizer notes that it has a 15-year history of working in the St. Louis, MO area. About 450 Pfizer employees working in various locations in the area will come together at the new site, and an additional 80 are expected to be hired “in coming years.”
The capital investment figure was not included in the news release; however, Pfizer noted that as part of a “strategic incentives” program of financial support from the state and St. Louis County, Pfizer is donating $20,000 to a local school district.